Skip to content

BioPharmChina

Covering China's BioPharma industry

BioPharmChina

Covering China's BioPharma industry

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Close

Search

Subscribe

BioPharmChina

Covering China's BioPharma industry

BioPharmChina

Covering China's BioPharma industry

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Home
Disease Areas
- Oncology
- Immunology
- Autoimmune
- I&I
- Metabolic
- Respiratory
- Cardiovascular
- Ophthalmology
- Neurology
- Rare Diseases
Clinical Trials
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- IIT
Financing
Manufacturing
Regulatory
- FTD
- BTD
- IND
- NDA/BLA
- Approvals
Deals
- M&A
- Partnerships
Events
Companies

Close

Search

Subscribe

Browse Category

M&A

0 Article

Nothing found!

It looks like nothing was found here!

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Email

I accept the privacy policy

Latest Articles

Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3

Info

Email
contact@biopharmchina.com

Location
San Francisco, CA, USA

X
Facebook